138
Views
31
CrossRef citations to date
0
Altmetric
Original Research

Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding

, , , , , & show all
Pages 611-626 | Published online: 23 Nov 2017

References

  • OyinlolaJOCampbellJKousoulisAAIs real world evidence influencing practice? A systematic review of CPRD research in NICE guidancesBMC Health Serv Res20161629927456701
  • SchmidtMPedersenLSorensenHTThe Danish Civil Registration System as a tool in epidemiologyEur J Epidemiol201429854154924965263
  • SturmerTJonsson FunkMPooleCBrookhartMANonexperimental comparative effectiveness research using linked healthcare databasesEpidemiology201122329830121464649
  • WettermarkBZoegaHFuruKThe Nordic prescription databases as a resource for pharmacoepidemiological research – a literature reviewPharmacoepidemiol Drug Saf201322769169923703712
  • International conference on harmonisation; guidance on statistical principles for clinical trials; availability – FDA. NoticeFed Regist199863179495834959810185190
  • HernanMAHernandez-DiazSBeyond the intention-to-treat in comparative effectiveness researchClin Trials201291485521948059
  • SuissaSInhaled steroids and mortality in COPD: bias from unaccounted immortal timeEur Resp J2004233391395
  • SuissaSImmortal time bias in observational studies of drug effectsPharmacoepidemiol Drug Saf200716324124917252614
  • RothmanKJGreenlandSLashTLValidity in epidemiologic studiesRothmanKJGreenlandSLashTLModern Epidemiology3rd edPhiladelphia, PALippincott Williams & Wilkins2008
  • HernanMAHernandez-DiazSRobinsJMA structural approach to selection biasEpidemiology200415561562515308962
  • De BerardisGLucisanoGD’EttorreAAssociation of aspirin use with major bleeding in patients with and without diabetesJAMA2012307212286229422706834
  • Bibbins-DomingoKAspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statementAnn Intern Med20161641283684527064677
  • BrookhartMAPatrickARDormuthCAdherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effectAm J Epidemiol2007166334835417504779
  • HumphreyLLChanBKSoxHCPostmenopausal hormone replacement therapy and the primary prevention of cardiovascular diseaseAnn Intern Med2002137427328412186518
  • RayWADaughertyJRGriffinMRLipid-lowering agents and the risk of hip fracture in a Medicaid populationInj Prev20028427627912460961
  • JohannesdottirSAHorvath-PuhoEEhrensteinVSchmidtMPedersenLSorensenHTExisting data sources for clinical epidemiology: The Danish National Database of Reimbursed PrescriptionsClin Epidemiol2012430331323204870
  • SchmidtMSchmidtSASandegaardJLEhrensteinVPedersenLSorensenHTThe Danish National Patient Registry: a review of content, data quality, and research potentialClin Epidemiol2015744949026604824
  • CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
  • ParsonsLSReducing bias in a propensity score matched-pair sample using greedy matching techniquesSAS SUGI 26, Paper 214-26
  • FeinsteinARClinical biostatistics. XI. Sources of ‘chronology bias’ in cohort statisticsClin Pharmacol Ther19711258648795568260
  • GuessHABehavior of the exposure odds ratio in a case-control study when the hazard function is not constant over timeJ Clin Epidemiol19894212117911842585009
  • LundJLRichardsonDBSturmerTThe active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary applicationCurr Epidemiol Rep20152422122826954351
  • MorideYAbenhaimLEvidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic researchJ Clin Epidemiol19944777317377722586
  • RayWAEvaluating medication effects outside of clinical trials: new-user designsAm J Epidemiol2003158991592014585769
  • SuissaSAzoulayLMetformin and the risk of cancer: time-related biases in observational studiesDiabetes Care201235122665267323173135
  • HernanMASauerBCHernandez-DiazSPlattRShrierISpecifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJ Clin Epidemiol201679707527237061
  • HernanMACounterpoint: epidemiology to guide decision-making: moving away from practice-free researchAm J Epidemiol20151821083483926507306
  • HernanMARobinsJMUsing big data to emulate a target trial when a randomized trial is not availableAm J Epidemiol2016183875876426994063
  • VandenbrouckeJPearceNPoint: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology?Am J Epidemiol20151821082683326507305
  • HallGCSauerBBourkeABrownJSReynoldsMWLoCasaleRGuidelines for good database selection and use in pharmacoepidemiology researchPharmacoepidemiol Drug Saf2012211110
  • DreyerNASchneeweissSMcNeilBJGRACE principles: recognizing high-quality observational studies of comparative effectivenessAm J Manag Care201016646747120560690
  • BenchimolEISmeethLGuttmannAThe REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statementPLoS Med20151210e100188526440803
  • LundJLSturmerTToft-SorensenHBenefits and risks of aspirin useJAMA20123081110891090 author reply 109022990258